Neurogene doses first patient in high-dose cohort of NGN-401; safety data positive

Neurogene Inc.

First patient in Cohort 2 received high-dose NGN-401 in May 2024; well-tolerated to date.
Low-dose cohort (3 patients) shows no new treatment-related adverse events; all AEs mild/Grade 1.
No signs of MeCP2 overexpression toxicity, including in patient with mild genetic variant.
Company expects interim efficacy data from low-dose cohort in Q4 2024.
Neurogene is participating in FDA's START Pilot Program to accelerate NGN-401 development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.